Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis trial

Risk for future clinical outcomes is proportional to the severity of liver disease in patients with chronic hepatitis C virus (HCV). We measured disease severity by quantitative liver function tests (QLFTs) to determine cutoffs for QLFTs that identified patients who were at low and high risk for a clinical outcome. Two hundred and twenty‐seven participants in the Hepatitis C Antiviral Long‐term Treatment Against Cirrhosis (HALT‐C) Trial underwent baseline QLFTs and were followed for a median of 5.5 years for clinical outcomes. QLFTs were repeated in 196 patients at month 24 and in 165 patients at month 48. Caffeine elimination rate (kelim), antipyrine (AP) clearance (Cl), MEGX concentration, methionine breath test (MBT), galactose elimination capacity (GEC), dual cholate (CA) clearances and shunt, perfused hepatic mass (PHM), and liver and spleen volumes (by single‐photon emission computed tomography) were measured. Baseline QLFTs were significantly worse (P = 0.0017 to P < 0.0001) and spleen volumes were larger (P < 0.0001) in the 54 patients who subsequently experienced clinical outcomes. QLFT cutoffs that characterized patients as “low” and “high risk” for clinical outcome yielded hazard ratios ranging from 2.21 (95% confidence interval [CI]: 1.29‐3.78) for GEC to 6.52 (95% CI: 3.63‐11.71) for CA clearance after oral administration (Cloral). QLFTs independently predicted outcome in models with Ishak fibrosis score, platelet count, and standard laboratory tests. In serial studies, patients with high‐risk results for CA Cloral or PHM had a nearly 15‐fold increase in risk for clinical outcome. Less than 5% of patients with “low risk” QLFTs experienced a clinical outcome. Conclusion: QLFTs independently predict risk for future clinical outcomes. By improving risk assessment, QLFTs could enhance the noninvasive monitoring, counseling, and management of patients with chronic HCV. (HEPATOLOGY 2012)

[1]  Giacomo Germani,et al.  The relationship between liver disease stage and liver fibrosis: a tangled web , 2010, Histopathology.

[2]  William M. Lee,et al.  Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  R. Fontana,et al.  Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C , 2010, Gut.

[4]  Xiaoping Zhou,et al.  Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside‐naive Chinese chronic hepatitis B patients , 2010, Journal of viral hepatitis.

[5]  H. Bonkovsky,et al.  Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long‐term treatment against cirrhosis trial , 2010, Hepatology.

[6]  H. Bonkovsky.  Prognostic Value of Ishak Fibrosis Stage: Findings from the HALT-C Trial , 2010 .

[7]  C. McClain,et al.  Obesity-induced hepatic hypoperfusion primes for hepatic dysfunction after resuscitated hemorrhagic shock. , 2009, Surgery.

[8]  J. Bosch,et al.  The clinical use of HVPG measurements in chronic liver disease , 2009, Nature Reviews Gastroenterology &Hepatology.

[9]  R. Sterling,et al.  Systematic review: non‐invasive methods of fibrosis analysis in chronic hepatitis C , 2009, Alimentary pharmacology & therapeutics.

[10]  A. Lawson.  Hepatitis C virus‐infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease? , 2009, Journal of viral hepatitis.

[11]  E. Schiff,et al.  Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. , 2009, Gastroenterology.

[12]  J. Hoefs,et al.  Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT‐C trial , 2009, Alimentary pharmacology & therapeutics.

[13]  William M. Lee,et al.  Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. , 2008, The New England journal of medicine.

[14]  O. Pappo,et al.  A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT , 2008, Journal of viral hepatitis.

[15]  A. fong,et al.  Utilization rates, complications and costs of percutaneous liver biopsy: a population‐based study including 4275 biopsies , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[16]  J. Hoefs,et al.  The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti‐viral Long‐term Treatment against Cirrhosis Trial 1 , 2008, Alimentary pharmacology & therapeutics.

[17]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[18]  L. Finelli,et al.  Changing trends in hepatitis C–related mortality in the United States, 1995‐2004 , 2007, Hepatology.

[19]  R. Myers,et al.  FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy , 2007, The American Journal of Gastroenterology.

[20]  J. Hoefs,et al.  Portal‐systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt , 2007, Alimentary pharmacology & therapeutics.

[21]  Ramon Planas,et al.  Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. , 2007, Gastroenterology.

[22]  Chia-Yen Dai,et al.  The incidence and risks of liver biopsy in non-cirrhotic patients: An evaluation of 3806 biopsies , 2007, Gut.

[23]  M. Ngu,et al.  Twenty‐year audit of percutaneous liver biopsy in a major Australian teaching hospital , 2006, Internal medicine journal.

[24]  Roger Williams.  Global challenges in liver disease , 2006, Hepatology.

[25]  R. Branch,et al.  Liver disease selectively modulates cytochrome P450–mediated metabolism , 2006, Clinical pharmacology and therapeutics.

[26]  J. Hoefs,et al.  Noninvasive evaluation of liver disease severity. , 2006, Clinics in liver disease.

[27]  M. De Luca,et al.  Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study , 2006, European journal of gastroenterology & hepatology.

[28]  S. Zeuzem,et al.  Chronic hepatitis C in patients with persistently normal alanine transaminase levels. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  F. Chang,et al.  Limitation of the model for end‐stage liver disease for outcome prediction in patients with cirrhosis‐related complications , 2006, Clinical transplantation.

[30]  William M. Lee,et al.  Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. , 2004, Controlled clinical trials.

[31]  R. Orlando,et al.  The effect of age on plasma MEGX concentrations. , 2003, British journal of clinical pharmacology.

[32]  H. Yoo,et al.  Relationship of the Model for End-Stage Liver Disease (MELD) Scale to Hepatic Encephalopathy, as Defined by Electroencephalography and Neuropsychometric Testing, and Ascites , 2003, American Journal of Gastroenterology.

[33]  L. Seeff,et al.  Natural history of chronic hepatitis C , 2002, Hepatology.

[34]  E. Schiff,et al.  Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.

[35]  F. Degos,et al.  Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey , 2000, Hepatology.

[36]  P. Kamath,et al.  A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.

[37]  H. Margolis,et al.  The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States , 2000, Hepatology.

[38]  J. Hoefs,et al.  Functional measurement of nonfibrotic hepatic mass in cirrhotic patients. , 1997, The American journal of gastroenterology.

[39]  J. Hoefs,et al.  The liver‐spleen scan as a quantitative liver function test: Correlation with liver severity at peritoneoscopy , 1995, Hepatology.

[40]  J. Hoefs,et al.  The liver-spleen scan as a quantitative liver function test : correlation with liver severity at peritoneoscopy , 1995 .

[41]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[42]  J. Hoefs,et al.  Perfused Kupffer cell mass , 1995, Digestive Diseases and Sciences.

[43]  A. Burroughs,et al.  Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. , 1995, Gut.

[44]  V. Armstrong,et al.  Influence of Gender on the Monoethylglycinexylidide Test in Normal Subjects and Liver Donors , 1994, Therapeutic drug monitoring.

[45]  K. Lindor,et al.  Outcome of Patients Hospitalized for Complications after Outpatient Liver Biopsy , 1993, Annals of Internal Medicine.

[46]  S. Preskorn,et al.  The Effect of Age on Plasma Levels of Nortriptyline , 1991 .

[47]  B J Ott,et al.  A 21-year experience with major hemorrhage after percutaneous liver biopsy. , 1990, Gastroenterology.

[48]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[49]  William M. Lee,et al.  Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. , 2010, Gastroenterology.

[50]  R. Levine,et al.  3 COLCHICINE VERSUS PEG-INTERFERON ALFA 2B LONG TERM THERAPY: RESULTS OF THE 4 YEAR COPILOT TRIAL , 2008 .

[51]  J. Barkin,et al.  Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis , 2008 .

[52]  A. Daly.  Significance of the Minor Cytochrome P450 3A Isoforms , 2006, Clinical pharmacokinetics.

[53]  A. Sanyal.  Mechanisms of Disease: pathogenesis of nonalcoholic fatty liver disease , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[54]  J. Bruzzi,et al.  Liver biopsy. , 2001, The New England journal of medicine.

[55]  P. Thampanitchawong,et al.  Liver biopsy:complications and risk factors. , 1999, World journal of gastroenterology.

[56]  M. Colombo,et al.  Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. , 1986, Journal of hepatology.

[57]  P. Gregory,et al.  Bleeding after liver biopsy. , 1981, The Western journal of medicine.